Working to Eradicate Gynecologic Cancers

Chandra Lovejoy, MS

Vice President of Regulatory Affairs
Endocyte, Inc.
3000 Kent Avenue
Suite A1-100
West Lafayette, IN
USA 47906

Papers:
448 - Poster Session B CA-125 as a response marker for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer: the PRECEDENT trial